The PROfound study showed that there was an increase in progression-free survival and overall survival (OS) among cohort A (which included PCa patients with at least one of the following mutations: BRCA1, BRCA2, or ATM mutations). The gene discussed is BRCA2; the disease is posterior cortical atrophy.